Mursla Bio helps shape the standardisation of EV-based liquid biopsy for clinical use

Mursla Bio participates in a unique global initiative to standardise the clinical use of novel EV-based biomarkers for liquid biopsy

Cambridge, UK, 4th October 2023: Mursla Bio is set to participate in the International Society of Extracellular Vesicle (ISEV) workshop to discuss optimal ways to translate EV-based biomarkers into clinical practice. This will include a focus on the regulatory requirements and commercial aspects. The workshop will feature the participation of The European Liquid Biopsy Society (ELBS).

Extracellular Vesicles (EVs), which contain multi-omics information from their parental cells, are among the most promising modalities for the next generation of liquid biopsy tests. Mursla Bio has long been at the forefront of developing technologies to introduce novel EV-based liquid biopsy tests to clinics. This involves the improved isolation of rare, information-rich EV subpopulations, such as tissue-derived EVs, and the removal of highly abundant confounding factors like protein aggregates and lipoproteins.

Mursla Bio is currently conducting a pioneering clinical study to implement the EV-based liquid biopsy approach in clinics (N=460). This study centers on developing cost-effective multi-omics signatures of liver-derived EVs in patients with hepatocellular carcinoma (HCC) and other chronic liver conditions. Interim results are expected by the end of the year.

The ISEV workshop, scheduled for 12-14 October 2023 in Aalborg, Denmark, will gather a select group of key opinion leaders including Mursla Bio’s representatives.


For more information contact:

Mursla Bio, Cambridge
Tel: +44 (0) 1223 928 141

About Mursla Bio
Mursla Bio (Cambridge, UK) is a techbio company, leveraging extracellular vesicle biology to deliver nextgen liquid biopsy and precision medicine tests. Its first product is an In Vitro Diagnostics test to significantly improve the early detection of liver cancer among high-risk populations, such that more individuals can benefit from curative and lifesaving treatments. Mursla Bio’s test is first-in-class and is differentiated from first generation liquid biopsy tests using circulating free DNA as it is tissue-specific, multi-omics and offers a real time snapshot of disease biology. Mursla Bio was selected as UK Life Sciences Innovator 2023 in the Diagnostics and Precision Medicine category.

Discover more: